|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.08|
There is one clinical trial.
Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.
Description: Hospital mortality will be death in the ICU during the same hospital admissionMeasure: Hospital mortality Time: Death in the Hospital (ICU or ward) before or at 6 months after enrollment
Description: Death in the ICU during the same hospital admission.Measure: ICU mortality Time: Death in the ICU at or after 90 days of enrollment
Description: Number of calendar days between admission and final discharge from ICU.Measure: ICU Length of Stay Time: Number of days in ICU with an average expected duration of 10 days.
Description: Number of calendar days between start and final liberation from mechanical ventilation.Measure: Duration of Mechanical Ventilation Time: Number of days of mechanical ventilation with an expected average duration of 8 days
Description: viral clearance from all sampled sites by day 3 after administration of CPMeasure: Viral load in tracheal aspirate Time: Serial levels in the first 28 days of enrollment
Description: Epidermal Growth Factor (EGF), Eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interferon(IFN)-γ, IFN-a2, Interleukin (IL)-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, Interferon gamma-induced protein (IP)-10, Monocyte Chemotactic Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1a, MIP-1β, Tumor Necrosis Factor-α (TNF-a), TNF-β, Vascular Endothelial Growth Factor (VEGF)Measure: Inflammatory markers, Time: Serial levels in the first 28 days of enrollment
Description: anti-MERS-CoV antibody level before and after administration of CP.Measure: Anti-MERS-CoV antibodies Time: Serial levels in the first 28 days of enrollment
Description: X ray changes at day 0, 1, 3, 7, 14, 21 and 28Measure: Chest X ray Time: Serial changes in the X ray till day 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports